1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

Adeona partners Intrexon in stock-for-tech deal for pulmonary arterial hypertension

 
• By Nancy Faigen

Adeona Pharmaceuticals, a development firm that does not have its own in-house R&D, has entered into a global collaboration with the synthetic biology company Intrexon whereby Adeona hopes to develop and commercialise a DNA-based treatment for pulmonary arterial hypertension (PAH). Adeona is 'buying' access to Intrexon's technology with its stock.

Adeona Pharmaceuticals, a development firm that does not have its own in-house R&D, has entered into a global collaboration with the synthetic biology company Intrexon whereby Adeona hopes to develop and commercialise a DNA-based treatment for pulmonary arterial hypertension (PAH). Adeona is 'buying' access to Intrexon's technology with its stock.

The deal structure, under which Intrexon will initially receive 9.995% of Adeona's stock (worth around $2.2 million on 21 November...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Cardiovascular

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 
• By Andrew McConaghie

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

More from Therapeutic Category

Boehringer Expands Eyecare Horizons With Palatin Collaboration

 
• By Andrew McConaghie

The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.

Third Sickle Cell Product From Pfizer’s Global Blood Buyout Hits Snag

 
• By Alaric DeArment

The drugmaker reported a negative Phase III study for inclacumab, after a partial clinical hold for osivelotor and pulling Oxbryta from the market.

Wegovy’s Win In MASH Gives Novo A Much-Needed Edge Over Lilly

 
• By Manas Mishra

Just days after discontinuing a Phase III trial for a separate MASH compound, Novo Nordisk has secured the US FDA’s accelerated approval for Wegovy to treat the fatty liver disease.